UnknownNot Applicable

Efficacy and Safety of Nexpowder™ for Non-variceal, Upper Gastrointestinal Bleeding

Singapore24 participantsStarted 2024-02

Plain-language summary

The purpose of this pilot clinical trial is to confirm the efficacy and safety of Nexpowder™ for hemostasis in pilot cohort of patients with NVUGIB in Singapore

Who can participate

Age range21 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males or females aged over 21 to 75 years
✓. Patients with confirmed nonvariceal, upper gastrointestinal bleeding
✓. Patients who voluntarily agree to the clinical trial with informed consent
✓. Patients who willing and able to comply with the study protocol

Exclusion criteria

✕. Patients with an uncorrected coagulation disorder (PLT\<50\*109/L, INR\>2)
✕. Patients who are known to be pregnant or in lactation
✕. Patients who have received another endoscopic treatment for the same part of the body within the days preceding the study
✕. Patients for whom endoscopic treatment is prohibited due to comorbidity
✕. Patients for whom the 30-day follow-up period is impossible
✕. Patients who have participated within the past month in other related clinical trials that could affect the results of the study
✕. Other cases in which participation in the study is judged inappropriate by the investigators

What they're measuring

endoscopic hemostasis

Timeframe: up to 24 hours

Trial details

NCT IDNCT06269588

SponsorChangi General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12

View on ClinicalTrials.gov More Gastrointestinal Hemorrhage trials